Literature DB >> 21472129

Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR.

Anastasia Pavlidou1, Maria Dalamaga, Christos Kroupis, George Konstantoudakis, Maria Belimezi, George Athanasas, Kleanthi Dimas.   

Abstract

AIM: To investigate three isoforms of survivin in colorectal adenocarcinomas.
METHODS: We used the LightCycler Technology (Roche), along with a common forward primer and reverse primers specific for the splice variants and two common hybridization probes labeled with fluorescein and LightCycler-Red fluorophore (LC-Red 640). Real time quantitative polymerase chain reaction (PCR) was performed on cDNAs from 52 tumor specimens from colorectal cancer patients and 10 unrelated normal colorectal tissues. In the patients group, carcinoembryonic antigen (CEA) and CA19-9 tumor markers were also measured immunochemically.
RESULTS: Wild type survivin mRNA isoform was expressed in 48% of the 52 tumor samples, survivin-2b in 38% and survivin-ΔΕx3 in 29%, while no expression was found in normal tissues. The mRNA expression of wild type survivin presented a significant correlation with the expression of the ratio of survivin-2b, survivin-ΔΕx3, survivin-2b/wild type survivin and survivin-ΔΕx3/wild type survivin (P < 0.001). The mRNA expression of wild-survivin and survivin-ΔΕx3 was related with tumor size and invasion (P = 0.006 and P < 0.005, respectively). A significant difference was found between survivin-2b and morphologic cancer type. Also, the ratio of survivin-ΔEx3/wild-survivin was significantly associated with prognosis. No association was observed between the three isoforms and grade, metastasis, Dukes stage and gender. The three isoforms were not correlated with CEA and CA19-9.
CONCLUSION: Survivin isoforms may play a role in cell apoptosis and their quantification could provide information about clinical management of patients suffering from colorectal cancer.

Entities:  

Keywords:  Apoptosis gene; Colorectal adenocarcinomas; Lightcycler; Real time quantitative polymerase chain reaction; Survivin; mRNA isoforms

Mesh:

Substances:

Year:  2011        PMID: 21472129      PMCID: PMC3070134          DOI: 10.3748/wjg.v17.i12.1614

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  45 in total

1.  Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA.

Authors:  Christos Kroupis; Aliki Stathopoulou; Eleni Zygalaki; Lisa Ferekidou; Maroulio Talieri; Evi S Lianidou
Journal:  Clin Biochem       Date:  2005-01       Impact factor: 3.281

2.  Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting.

Authors:  G Ambrosini; C Adida; G Sirugo; D C Altieri
Journal:  J Biol Chem       Date:  1998-05-01       Impact factor: 5.157

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

4.  Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas.

Authors:  Keiji Suga; Tetsuhisa Yamamoto; Yoshitaka Yamada; Shin-Ichi Miyatake; Toshimasa Nakagawa; Nobuhiko Tanigawa
Journal:  Oncol Rep       Date:  2005-05       Impact factor: 3.906

5.  Survivin splice variants regulate the balance between proliferation and cell death.

Authors:  Hugo Caldas; Yuying Jiang; Michael P Holloway; Jason Fangusaro; Csaba Mahotka; Edward M Conway; Rachel A Altura
Journal:  Oncogene       Date:  2005-03-17       Impact factor: 9.867

6.  Prognostic significance and different properties of survivin splicing variants in gastric cancer.

Authors:  Hua Meng; Caide Lu; Hideaki Mabuchi; Nobuhiko Tanigawa
Journal:  Cancer Lett       Date:  2004-12-28       Impact factor: 8.679

7.  Expression level of wild-type survivin in gastric cancer is an independent predictor of survival.

Authors:  Hua Meng; Cai-De Lu; Yu-Lei Sun; De-Jian Dai; Sang-Wong Lee; Nobuhiko Tanigawa
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

8.  Transcriptional expression of survivin and its splice variants in brain tumors in humans.

Authors:  Yoshitaka Yamada; Toshihiko Kuroiwa; Toshimasa Nakagawa; Yoshinaga Kajimoto; Takehiko Dohi; Haruhito Azuma; Motomu Tsuji; Kazuhiro Kami; Shin-Ichi Miyatake
Journal:  J Neurosurg       Date:  2003-10       Impact factor: 5.115

9.  Identification of a novel splice variant of the human anti-apoptopsis gene survivin.

Authors:  Adel Badran; Akira Yoshida; Keiko Ishikawa; Takanori Goi; Akio Yamaguchi; Takanori Ueda; Manabu Inuzuka
Journal:  Biochem Biophys Res Commun       Date:  2004-02-13       Impact factor: 3.575

10.  Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies.

Authors:  Hugo Caldas; Laura E Honsey; Rachel A Altura
Journal:  Mol Cancer       Date:  2005-03-02       Impact factor: 27.401

View more
  9 in total

1.  Protein Sam68 regulates the alternative splicing of survivin DEx3.

Authors:  Javier Gaytan-Cervantes; Carolina Gonzalez-Torres; Vilma Maldonado; Cecilia Zampedri; Gisela Ceballos-Cancino; Jorge Melendez-Zajgla
Journal:  J Biol Chem       Date:  2017-06-27       Impact factor: 5.157

2.  Clinicopathological significance of survivin expression in patients with cervical cancer: A systematic meta-analysis.

Authors:  Yibing Fan; Juan Chen
Journal:  Bioengineered       Date:  2017-01-04       Impact factor: 3.269

Review 3.  Clinico-pathologic relevance of Survivin splice variant expression in cancer.

Authors:  Rosalia de Necochea-Campion; Chien-Shing Chen; Saied Mirshahidi; Frank D Howard; Nathan R Wall
Journal:  Cancer Lett       Date:  2013-06-18       Impact factor: 8.679

Review 4.  Association of survivin splice variants with prognosis and treatment of breast cancer.

Authors:  Anastasia Pavlidou; Christos Kroupis; Kleanthi Dimas
Journal:  World J Clin Oncol       Date:  2014-12-10

5.  Expression of survivin and its four splice variants in colorectal cancer and its clinical significances.

Authors:  Quan-Xing Ge; Yu-Yuan Li; Yu-Qiang Nie; Wen-Ge Zuo; Yan-Lei Du
Journal:  Med Oncol       Date:  2013-03-15       Impact factor: 3.064

6.  Targeting survivin as a potential new treatment for chondrosarcoma of bone.

Authors:  Y de Jong; J G van Oosterwijk; A B Kruisselbrink; I H Briaire-de Bruijn; G Agrogiannis; Z Baranski; A H G Cleven; A-M Cleton-Jansen; B van de Water; E H J Danen; J V M G Bovée
Journal:  Oncogenesis       Date:  2016-05-09       Impact factor: 7.485

7.  High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth.

Authors:  Marieke A de Graaff; Shruti Malu; Irma Guardiola; Alwine B Kruisselbrink; Yvonne de Jong; Willem E Corver; H Gelderblom; Patrick Hwu; Torsten O Nielsen; Alexander J Lazar; Neeta Somaiah; Judith V M G Bovée
Journal:  Transl Oncol       Date:  2017-06-24       Impact factor: 4.243

8.  Of mice and men: Considerations on adipose tissue physiology in animal models of obesity and human studies.

Authors:  Ioannis G Lempesis; Dimitrios Tsilingiris; Junli Liu; Maria Dalamaga
Journal:  Metabol Open       Date:  2022-08-24

9.  Subcellular Localization of Survivin Determines Its Function in Cardiomyocytes.

Authors:  Tien-Jui Tsang; Ying-Chang Hsueh; Erika I Wei; David J Lundy; Bill Cheng; You-Tzung Chen; Shoei-Shen Wang; Patrick C H Hsieh
Journal:  Theranostics       Date:  2017-10-13       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.